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Hôpital Lyon Sud, Université de Lyon, Centre Européen de Nutrition pour la Santé, Lyon, FranceDialysis patients exhibit an inverse, L- or U-shaped
association between blood pressure and mortality risk, in
contrast to the linear association in the general population.
We prospectively studied 9333 hemodialysis patients in
France, aiming to analyze associations between predialysis
systolic, diastolic, and pulse pressure with all-cause
mortality, cardiovascular mortality, and nonfatal
cardiovascular endpoints for a median follow-up of 548
days. Blood pressure components were tested against
outcomes in time-varying covariate linear and fractional
polynomial Cox models. Changes throughout follow-up
were analyzed with a joint model including both the time-
varying covariate of sequential blood pressure and its slope
over time. A U-shaped association of systolic blood
pressure was found with all-cause mortality and of both
systolic and diastolic blood pressure with cardiovascular
mortality. There was an L-shaped association of diastolic
blood pressure with all-cause mortality. The lowest hazard
ratio of all-cause mortality was observed for a systolic
blood pressure of 165 mm Hg, and of cardiovascular
mortality for systolic/diastolic pressures of 157/90 mm Hg,
substantially higher than currently recommended values
for the general population. The 95% lower conﬁdence
interval was approximately 135/70 mm Hg. We found no
signiﬁcant correlation for either systolic, diastolic, or pulse
pressure with myocardial infarction or nontraumatic
amputations, but there were signiﬁcant positive
associations between systolic and pulse pressure with
stroke (per 10-mm Hg increase: hazard ratios 1.15, 95%
conﬁdence interval 1.07 and 1.23; and 1.20, 1.11 and 1.31,
respectively). Thus, whereas high pre-dialysis blood
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674blood pressure may be both harmful and a proxy for
comorbid conditions leading to premature death.
Kidney International (2016) 90, 674–684; http://dx.doi.org/10.1016/
j.kint.2016.05.025
KEYWORDS: cardiovascular disease; hemodialysis; hypertension
Copyright ª 2016, International Society of Nephrology. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
M ore than 2 million patients are receiving long-termdialysis therapy worldwide, and their survival rateis unacceptably low. In the general population, the
risk of cardiovascular and all-cause mortality increases
continuously and linearly with the increase in blood pressure
(BP), without any evidence of a threshold.1 Conversely,
reduction in BP by antihypertensive drugs decreases the car-
diovascular risk in proportion to the BP-lowering effect, albeit
with a small residual risk.2 Recent evidence pointed to a J-
curve association between BP and mortality in elderly adults
and patients with pre-existing coronary artery disease.3,4 The
risk of mortality is higher at lower levels of BP achieved under
treatment. The nadir of the J curve is considered the target BP,
at least in patients with a high coronary risk, although the
value of the precise inﬂection point is still a matter of debate.
In dialysis patients, nearly all observational studies have
reported a U-shaped or even an L-shaped association between
BP and all-cause mortality, with higher mortality at low BP
values and either no or only a small increase in mortality with
increasing BP.5–10 These paradoxical ﬁndings have been
coined “reverse epidemiology” as they largely differ from the
association observed in the general population and have
generated some form of therapeutic nihilism regarding the
treatment of hypertension in the dialysis population. For
example, data from a large US cohort indicates that the BP of
as many as 60% of dialysis patients was either untreated or
inadequately treated, whereas the prevalence of arterial hy-
pertension was nearly 90%.11
Several explanations, which are not mutually exclusive,
have been proposed to explain the so-called reverse epidemi-
ology, including poor assessment of BP, measurement of the
wrong components of BP (i.e., pulse pressure [PP] vs. systolicKidney International (2016) 90, 674–684
T Hannedouche et al.: Blood pressure and survival in hemodialysis c l i n i ca l i nves t iga t ionBP [SBP]),12 confounding factors affecting the association
between BP and mortality, and interference of antihyperten-
sive drugs, most of which also have cardioprotective effects.
In the current study, we took advantage of the large obser-
vational prospective French Observatory cohort of chronic
hemodialysis patients to clarify the association between BP and
mortality or morbidity in patients on long-term hemodialysis.RESULTS
Patient population
The study sample consisted of 9333 prospectively enrolled
long-term hemodialysis patients, representing w30% of the
total hemodialysis population in France. Participation was
proposed to a random draw of 400 nephrologists from a
national database to ensure at least 250 nephrologists
participating on a voluntary basis, and the center selection
was representative of the overall population compared with
the national French Renal Epidemiology and Information
Network (REIN) registry.13 Distribution of age, sex, and
initial comorbidities was similar to that of the prevalent REIN
cohort in the year 2010 (Table 1), although the proportions of
patients with diabetes and those with a history of cardiovas-
cular disease were slightly underrepresented.
Of the whole cohort, data on 1141 patients were provided
only at study entry and were not available later on. These
patients were therefore excluded from survival analyses. At
the ﬁnal visit for the studied 9333 patients, 57.0% (n ¼ 5317)
remained on dialysis treatment, 20.9% (n ¼ 1946) had died,Table 1 | Patient demographic characteristics, baseline
characteristics, and prescribed treatments at study entry
Observatory
cohort
REIN Registry
2010
Age, yr 67.5  14.7 67.5  15.6
Male, n (%) 5546 (59.4) (60.0)
Body mass index, kg/m2 25.0  5.3 24.7  5.4
Duration of dialysis at study entry,
mo
44 (23:82) 3.0
History of cardiovascular disease,
n (%)
5404 (57.9) (59.4)
Diabetes mellitus, n (%) 2606 (27.9) (35.9)
Systolic blood pressure, mm Hg 137  22 NA
Diastolic blood pressure, mm Hg 71  14 NA
Pulse pressure, mm Hg 66  19 NA
Antihypertensive drugs, n (%) 5423 (58.1) NA
Serum phosphate, mmol/l – mg/dl 1.58 (0.52) – 4.87 (1.58) NA
Serum total calcium, mmol/l –
mg/dl
2.20 (0.19) – 8.86 (0.76) NA
Serum albumin (technique-
corrected), g/l
38.8  5.0 35.8  5.2
Plasma iPTH (kit-corrected), pg/ml 228 (123:395) NA
Normalized protein catabolic rate,
g/kg/day
1.11  0.36 NA
Serum C-reactive protein, mg/l 5 (2.4:12.1) NA
Blood hemoglobin, g/dl 11.5  1.4 11.3  1.4
iPTH, intact parathyroid hormone; NA, not available.
Continuous variables are expressed as mean  SD for normally distributed data and
median (Q1:Q3) (25th and 75th percentile values) for nonnormally distributed data
(n ¼ 9333). Data from the nationwide REIN registry in France, year 2010, are given in
the right column for comparison purposes.
Kidney International (2016) 90, 674–68416.0% (n ¼ 1492) had been lost to follow-up, and 6.2%
(n ¼ 578) had undergone renal transplantation. The
mean  SD and median (25th and 75th percentile values
[Q1:Q3]) duration of follow-up was 550  290 and 548 (245:
914) days, respectively. The ﬂowchart of patients included in
the ﬁnal analysis is presented in Supplementary Figure S1.
At study entry, the mean  SD age of the patient popu-
lation was 67.5  14.7 years (59.4% males) with a median
hemodialysis vintage of 44 months. More than one-half of the
population (57.9%) had a history of cardiovascular disease
(Table 1).
A total of 8130 patients with complete data obtained for
BP, sex, age, dialysis vintage, serum values of corrected al-
bumin, C-reactive protein, phosphate and uncorrected total
calcium, plasma levels of intact parathyroid hormone (PTH),
blood hemoglobin concentrations, diabetes, history of car-
diovascular disease and smoking, and antihypertensive ther-
apy were included in the Cox survival analyses. There were
1717 deaths (21.1%), 788 of which were cardiovascular deaths
(45.9%). The remaining patients were censored for renal
transplantation (n ¼ 502, 6.2%), lost to follow-up (n ¼ 1373,
16.9%), or end of the study (n ¼ 4538, 55.8%).
There were 826 major cardiovascular events in 769 patients
(8.2%), including 353 nonfatal myocardial infarctions, 176
nonfatal strokes, and 297 nontraumatic amputations.
BP and mortality (all-cause and cardiovascular mortality)
Due to the U- or L-shaped hazard ratios (HRs) among SBP,
DBP, or PP and all-cause or cardiovascular mortality, frac-
tional polynomials of degree 2 were used to model these
3 parameters in the Cox analyses (Table 2). There was a
U-shaped association of SBP with all-cause mortality
(Figure 1a) and of SBP and DBP with cardiovascular mor-
tality (Figure 2a and b), an L-shaped association of DBP
(Figure 1b) and PP with all-cause mortality, and of PP with
cardiovascular mortality. However, after adjustment for SBP,
the association between PP and cardiovascular mortality was
no longer signiﬁcant.
The nadir of SBP, at which the all-cause mortality risk was
at its lowest, was 165 mm Hg; however, due to the L-shaped
association, there was no particular DBP value that was
indicative of minimal risk.
For cardiovascular mortality, the lowest HR was observed
for an SBP value of 157 mm Hg and a DBP value of
90 mm Hg. The lower limits of the 95% conﬁdence interval
were w135/70 mm Hg (Figure 1b).
Interestingly, compared with the baseline fractional poly-
nomials of degree 2 Cox model (using initial BP only), the
time-varying covariate (TVC) fractional polynomials of de-
gree 2 Cox model was signiﬁcantly superior and had a lower
deviance (21,365 vs. 28,507 for all-cause mortality and 9893
vs. 13,164 for cardiovascular mortality) but nonetheless
yielded similar results, that is, a similar U-shaped association
between SBP and all-cause and cardiovascular mortality,
respectively (data not shown). However, the nadir of SBP for
the baseline fractional polynomials of degree 2 Cox model675
Table 2 | HRs of covariates in a multivariate Cox model for all-cause and cardiovascular mortality (sex, age, and dialysis vintage
are forced)
Covariates
All-cause mortality Cardiovascular mortality
HR P value 95% CI HR P value 95% CI
Female sex 0.93 0.176 0.83–1.03 0.90 0.183 0.76–1.05
CV history 1.43 <0.001 1.28–1.60 2.21 <0.001 1.84–2.66
Diabetes 1.18 0.002 1.06–1.31 1.54 <0.001 1.33–1.79
Antihypertensive treatment 0.83 <0.001 0.75–0.91 0.84 0.017 0.73–0.97
Smoking
Ex 1.08 0.212 0.95–1.23 1.06 0.529 0.88–1.27
Yes 1.35 <0.001 1.16–1.59 1.35 0.009 1.08–1.69
Age, yr 1.04 <0.001 1.04–1.05 1.04 <0.001 1.03–1.05
Albumin, g/l 0.95 <0.001 0.94–0.96 0.98 0.005 0.96–0.99
Hemoglobin, g/dl 0.929 <0.001 0.895–0.964 0.921 0.002 0.874–0.970
Dialysis vintage, mo 0.99 0.17 0.99–1.01 1.00 0.579 0.99–1.00
CRP, mg/l 1.01 <0.001 1.004–1.01 1.00 <0.001 1.00–1.01
Fractional polynomialsa Coeff. Coeff.
Phosphate, mmol/l [2] 0.08 0.025 0.01–0.15 0.05 0.175 0.02 to 0.13
Phosphate, mmol/l [2] 0.03 0.036 0.00–0.07 0.06 0.004 0.02–0.11
Total calcium, mmol/l [2] 7.39 <0.001 4.20–10.58 11.09 <0.001 7.81–14.36
Total calcium, mmol/l [0.5] 9.44 <0.001 14.56 to 4.32 14.99 <0.001 21.00 to 8.99
Intact PTH, pg/ml [0] 0.10 0.006 0.18 to 0.03 0.06 0.25 0.17 to 0.04
Intact PTH, pg/ml [1] 0.39 0.004 0.13–0.65 0.31 0.083 0.04 to 0.67
CI, conﬁdence interval; CRP, C-reactive protein; CV, cardiovascular; HR, hazard ratio; PTH, parathyroid hormone.
aValues in brackets represent the powers used in the fractional polynomials for the best ﬁt:
P [2 2]: ln(HR) ¼ (b1  [P]2) þ (b2  [P]2) þ bk Xk
Total calcium [2 0.5]: ln(HR) ¼ (b3  [Ca]2) þ (b4  [Ca]0.5) þ bk Xk
Intact PTH [0 1]: ln(HR) ¼ (b5  ln[iPTH]) þ (b6  [iPTH]) þ bk Xk
b1–b6: coefﬁcients. bk Xk represents the k other covariates.
c l i n i ca l i nves t iga t i on T Hannedouche et al.: Blood pressure and survival in hemodialysiswas lower (146 mm Hg vs. 165 mm Hg for all-cause mortality
and 150 mm Hg vs. 157 mm Hg for cardiovascular mortality).
Interactions
Interactions to test were chosen among the covariates
commonly known to be associated with BP variation, namely
age, serum albumin, diabetes, and cardiovascular and smok-
ing history.
The U-shaped association of SBP with all-cause or car-
diovascular mortality was tested for potential interactions
with continuous variables including age and serum albumin
(at inclusion and as a TVC), and qualitative variables
including diabetes status, cardiovascular history, smoking
habit, dialysis vintage (incident,#1 year patients or prevalent,
>1 year patients), and treatment with antihypertensive drugs.
Overall, the U-shaped association was similar for all tested
variables (including treatment with antihypertensive drugs)
and all-cause and cardiovascular mortality, with no signiﬁcant
interaction (Figure 3).
Joint models
Joint models were subsequently used to further characterize
the associations between the trend in BP variations over time
and outcomes. When the slope of the variable was added in
the survival submodel, there was an association between SBP
and PP with all-cause but not cardiovascular mortality. Spe-
ciﬁcally, a slight increase in SBP or PP rate of change over
time (þ1 mm Hg/6 months) was signiﬁcantly associated
with a decrease in all-cause but not cardiovascular mortality676(SBP: HR 0.77 [0.62:0.96], P ¼ 0.018; PP: HR 0.04
[0.03:0.05], P < 0.001).
BP and cardiovascular events
In the time-varying component–adjusted Cox model, neither
SBP nor DBP or PP was predictive of myocardial infarction or
nontraumatic amputation, except PP for nontraumatic
amputation (per 10-mm Hg increase: HR 1.10 [1.03:1.17],
P ¼ 0.004, even when adjusting for SBP or DBP). However,
both SBP and PP had predictive power for stroke (per 10-mm
Hg increase: HR 1.15 [1.07:1.23], P < 0.001; HR 1.19
[1.10:1.30], P < 0.001, respectively). The predictive power of
PP for stroke remained signiﬁcant when adjusted for either
SBP or DBP (HR 1.16 [1.01:1.34], P ¼ 0.033; HR 1.20
[1.11:1.31], P < 0.001. respectively).DISCUSSION
In this nationwide prospective study of patients receiving
hemodialysis therapy, we found a U-shaped association of
SBP with all-cause mortality, as well as both SBP and DBP
with cardiovascular mortality, and an L-shaped association
between DBP and all-cause mortality, conﬁrming previous
mostly retrospective studies.5–10 Of particular interest, the
predictive power of low BP for mortality was readily apparent
using only 1 inclusion value of BP and was only slightly
improved by the TVC model that integrated all BP values
recorded over time.
Agarwal14 proposed a hypothetical model to explain this
apparently paradoxical observation also found in populationsKidney International (2016) 90, 674–684
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Figure 1 | Multivariate-adjusted hazard ratios (95% conﬁdence intervals) of all-cause mortality associated with systolic blood pressure
(a) and diastolic blood pressure (b). Values were calculated in time-varying covariate Cox models using fractional polynomials for the blood
pressures and adjusted for sex, age, dialysis vintage, serum values of corrected albumin, C-reactive protein, phosphate, and uncorrected total
calcium, plasma corrected intact parathyroid hormone level, blood hemoglobin concentration, use of antihypertensive therapy, diabetes
mellitus, and history of cardiovascular disease and smoking. The histograms depict the number of patients at inclusion for each incremental
bracket of 5 mm Hg. Powers of fractional polynomials: SBP [2 2], DBP [2 2] (see explanation in legend of Table 2). DBP, diastolic blood
pressure; SBP ¼ systolic blood pressure.
T Hannedouche et al.: Blood pressure and survival in hemodialysis c l i n i ca l i nves t iga t ionwith other chronic diseases such as heart failure. This author
suggested that the U curve describing the association between
BP and outcomes in dialysis patients may result from the
summation of different associations in 2 discrete patient
subgroups. The ﬁrst subgroup with heart failure would
exhibit an inverse association between BP and mortality,
similar to that observed in patients with advanced chronic
heart failure but in the absence of chronic kidney disease. In
these patients, low BP would be a proxy for low cardiac
output and, hence, closely associated with worse outcomes inKidney International (2016) 90, 674–684the short term. The second group would correspond to pa-
tients without heart failure but with arterial hypertension as a
consequence of sympathetic activation, volume overload, and
arterial stiffness. These patients would be primarily exposed
to the deleterious effects of hypertension and exhibit the
typical direct association between BP and mortality over the
long term. Accordingly, among patients on hemodialysis, the
ability to raise an elevated blood pressure further in response
to ﬂuid accumulated between hemodialysis sessions may
represent a sign of relative health. However, the same677
50 70 90 110 130 150 170 190 210 230
SBP (mm Hg)
50 70 90 110 130 150 170 190 210 230
SBP (mm Hg)
40 60 80 100 120
DBP (mm Hg)
40 60 80 100 120
DBP (mm Hg)
1600
1200
800
400
0
Pa
tie
nt
s
H
az
ar
d 
Ra
tio
H
az
ar
d 
Ra
tio
0
1
2
3
4
5
6
1200
1000
800
600
400
200
0
0
1
2
3
4
Pa
tie
nt
s
a
b
Figure 2 | Multivariate-adjusted hazard ratios (95% conﬁdence intervals) of cardiovascular mortality associated with systolic blood
pressure (a) and diastolic blood pressure (b). Values were calculated in time-varying covariate Cox models using fractional polynomials for
the blood pressures and adjusted for sex, age, dialysis vintage, serum values of corrected albumin, C-reactive protein, phosphate, and un-
corrected total calcium, plasma corrected intact parathyroid hormone level, blood hemoglobin concentration, use of antihypertensive therapy,
diabetes mellitus, and history of cardiovascular disease and smoking. The histograms depict the number of patients at inclusion for each
incremental bracket of 5 mm Hg. Powers of fractional polynomials: SBP [2 2], DBP [2 2] (see explanation in the footnote in Table 2). DBP,
diastolic blood pressure; SBP, systolic blood pressure.
c l i n i ca l i nves t iga t i on T Hannedouche et al.: Blood pressure and survival in hemodialysisU-shaped association was found among hemodialyzed par-
ticipants with preserved ejection fraction.15
Evidence of reverse causality with a U-shaped association
between BP and mortality has been limited to short-term
observations and disappeared with prolonged follow-up. In
agreement with the phenomenon of reverse causality, 1 study
found that low SBP was associated with increased mortality in
the ﬁrst 2 years after inception, whereas the usual adverse
effect of high BP on survival became apparent only after 3
years.7 However, in the current study, sensitivity analyses678found a similar U-shaped association when excluding
comorbidities from the model (age, diabetes, and previous
cardiovascular disease) and also dialysis vintage, supporting a
more direct, potentially causal link between low BP and
mortality. Indeed, these patients are more prone to intra-
dialytic hypotension and may experience organ hypo-
perfusion and myocardial stunning during aggressive
ultraﬁltration,16,17 especially those with high degrees of pre-
existing myocardial ﬁbrosis and myocyte/capillary
mismatch.18 Accordingly, a recent study showed that dialysisKidney International (2016) 90, 674–684
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Figure 3 | Multivariate-adjusted hazard ratios (95% conﬁdence intervals) of all-cause mortality associated with systolic blood pressure
according to cardiovascular history (0 [ no, 1 [ yes) (a), antihypertensive treatment (0 [ no, 1 [ yes) (b), and prevalent (dialysis
vintage >12 months) versus incident (£12 months) patients (continued).
T Hannedouche et al.: Blood pressure and survival in hemodialysis c l i n i ca l i nves t iga t ion
Kidney International (2016) 90, 674–684 679
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Figure 3 | (Continued) (c). Values were calculated in time-varying covariate Cox models using fractional polynomials for systolic blood pressure
and adjusted for sex, age, dialysis vintage, serum values of corrected albumin, C-reactive protein, phosphate, and uncorrected total calcium,
plasma corrected intact parathyroid hormone level, blood hemoglobin concentration, use of antihypertensive therapy, diabetes mellitus, and
history of cardiovascular disease and smoking. The histograms depict the number of patients at inclusion for each incremental bracket of
5 mm Hg. CV, cardiovascular; SBP, systolic blood pressure.
c l i n i ca l i nves t iga t i on T Hannedouche et al.: Blood pressure and survival in hemodialysiscenters with a greater proportion of hemodialysis patients
reaching the recommended target, that is, SBP <140 mm Hg,
had higher rates of symptomatic intradialytic hypotension.16
Similarly, a higher mortality rate was found with higher
perdialytic BP decreases in a large cohort of hemodialysis
patients.19,20
A recent study showed that the U-shaped association be-
tween BPandmortality was not present when BPwasmeasured
out of the dialysis unit.15 Indeed, this study found a direct,
quasilinear association between out-of-the dialysis-unit SBP
and mortality. The sample size of the cohort was relatively
small, however, and included highly selected patients (who
volunteered to enroll in the CRIC [Chronic Renal Insufﬁciency
Cohort] study). Of note, “standardized BP measurement
out-of-the-dialysis-unit” referred in this study to sitting SBP
recordings that apparently were performed only once in the
majority of patients, a potential limitation of the study.
We also found a weak association between a progressive
decrease in SBP and an increase in all-cause mortality
over a median follow-up of 458 days. As such an associa-
tion was not observed for cardiovascular mortality, this
suggests that decreasing SBP within months before death
may result from, rather than cause, the acute illness ulti-
mately leading to death.8 Thus, lower BP may well be a680marker of comorbid conditions not entirely captured by
other scores.
With some uncertainty related to the wide 95% conﬁdence
interval, the U-shaped association between BP and either all-
cause or cardiovascular mortality allows one to speculate on
“optimal” BP targets in hemodialysis patients (i.e., BP values
associated with the lowest outcome risk—still a controversial
issue). The best outcomes in our study were associated with
predialysis SBP/DBP values of 157/90 mm Hg, a ﬁgure sub-
stantially higher than that proposed by current, although
somewhat dated, recommendations of <140/90 mm Hg
and <130/80 mm Hg, before and after the hemodialysis
session, respectively.21,22
In the higher range of BP values, the conﬁdence interval
was too wide to secure an upper limit beyond which mortality
would increase. Only 2% to 3% of the patients had a pre-
dialysis SBP $180 mm Hg at any given time, an insufﬁcient
statistical power to detect an effect of very high BP on mor-
tality. However, the association was more robust for low BP
and increased mortality risk.
The optimal predialysis BP range may be higher than
predicted based on data from the general population because
predialysis BP represents the peak of the 48 to 72 hour
interdialytic cycle and hypervolemia. In addition, patients areKidney International (2016) 90, 674–684
T Hannedouche et al.: Blood pressure and survival in hemodialysis c l i n i ca l i nves t iga t ionstressed immediately before the puncture is made to gain
vascular access for hemodialysis, thus causing an over-
estimation of average BP. Moreover, nephrologists often
instruct hemodialysis patients to withhold antihypertensive
drugs on the dialysis day for fear of intradialytic hypotension,
a practice that would further overestimate BP relying on
predialysis measurements. Agarwal et al.23 reported an
average overestimation by 13 mm Hg of casual predialysis
SBP measurements compared with 48-hour ambulatory BP
monitoring.
In light of this, our data are compatible with the view that
intentional decreases in predialysis values of <135 mm Hg
for SBP and <70 mm Hg for DBP should be avoided
whenever possible. These data are suggestive of recent
ﬁndings in nondiabetic patients with non-dialysis chronic
kidney disease in which the combination of low SBP and low
DBP was associated with the highest mortality rates.24 In
addition, DBP values <w70 mm Hg appear to confer
increased mortality rates even in patients with SBP within
the normal range.
There are only scarce data in the literature on the as-
sociation between BP and nonfatal cardiovascular com-
plications in hemodialysis patients, likely because these
events are harder to be accurately captured in retrospective
studies. Stidley et al.7 found an inverse association of low
SBP and DBP with atherosclerotic cardiovascular disease
in a retrospective study done in an incident cohort. In the
current series, however, we found a more direct linear
correlation of SBP and PP with stroke, in line with a
causal association, as observed in the general population.
In contrast, there was no association of SBP, DBP, or PP
with nonfatal myocardial infarctions or nontraumatic
amputations. Our failure to observe an increase in the
incidence of myocardial infarction at low SBP or DBP
values appears to contradict the hypothesis of increased
mortality at low BP secondary to worsening of myocardial
ischemia in response to reduced coronary perfusion dur-
ing diastole.
The major strengths of our study include a large
contemporary and representative nationwide cohort, repre-
sentingw30% of the total hemodialysis patient population in
France, as well as the use of averaged BP values from
numerous measurements over an extended follow-up period.
In addition, data were collected prospectively over 30 months
with <16% of loss to follow-up, while outcomes were pre-
deﬁned end points including both all-cause and cardiovas-
cular mortality and other prespeciﬁed well-deﬁned
cardiovascular events. Finally, analyses were adjusted for case
mix and a large number of covariates as potential con-
founders, including serum albumin, serum C-reactive pro-
tein, and major comorbidities.
However, several limitations also need mentioning. First,
BP measurements were obtained during routine patient care
rather than with the standard Kidney Disease Outcomes
Quality Initiative protocol.21 As already mentioned, there may
be a signiﬁcant overestimation between usual andKidney International (2016) 90, 674–684standardized BP measurements among hemodialysis pa-
tients.23 Predialysis BP is, however, still supported by Kidney
Disease Outcomes Quality Initiative guidelines because of
better applicability in clinical practice.
Second, per- and postdialysis BP values were not collected
in our study. In 1 study, postdialysis BP was found to best
correlate with mean interdialytic BP assessed by ambulatory
BP monitoring.25 However, the association of postdialysis BP
and outcomes remains controversial. In a small hemodialysis
patient cohort (N ¼ 115), an increase >5 mm Hg in post-
dialysis SBP was associated with higher mortality (HR 3.9),26
a feature thought to reﬂect persistent hypervolemia. However,
in the prospective HEMO (Hemodialysis) study, postdialysis
BP was not consistently associated with clinical outcome.8
Similarly, in the large international DOPPS (Dialysis Out-
comes and Practice Patterns Study), no interaction effect was
found between predialysis SBP and changes in postdialysis
SBP.9
Third, information on cardiovascular function or echo-
cardiography was not collected, which could have helped to
elucidate the observed association between low BP, cardiac
dysfunction, and higher mortality. However, a similar
U-shaped association between BP and mortality was found
among hemodialyzed participants with preserved ejection
fraction.15
Fourth, there was no available information on speciﬁc
antihypertensive drugs, some of which may have car-
dioprotective effects beyond BP lowering, such as beta-
blockers and renin-angiotensin system blockers, although
we did have information on whether patients were
receiving antihypertensive drugs. We did not ﬁnd any
interaction in the U-shaped association between SBP and
mortality and treatment or no treatment with antihyper-
tensive drugs. There may be an indication bias, however,
because beta-blockers, renin-angiotensin system blockers,
and diuretics can be prescribed for both hypertension and
heart failure. As to the possible role of antihypertensive
drugs in the so-called reverse epidemiology phenomenon,
there are only a few randomized, controlled trials in dial-
ysis patients. Two recent meta-analyses concluded that
there was a beneﬁt of these treatments, with an overall 20%
reduction in mortality.27,28 It is unknown whether part of
this effect may be attributed to an intrinsic cardioprotective
effect (e.g., beta-blocker in dialysis patients with congestive
heart failure).29
Fifth, our cohort has a slight underrepresentation of dia-
betic patients compared with the global dialysis patient
population in France and some other countries, which may
have affected our results and conclusions.
Finally, as with all observational studies, causality cannot
be determined, and adjustment for confounders is limited to
those that are recognized and measured.
Conclusion and perspectives
In this large, nationwide, prospective hemodialysis patient
cohort, we were able to conﬁrm the U-shaped association681
c l i n i ca l i nves t iga t i on T Hannedouche et al.: Blood pressure and survival in hemodialysisbetween SBP and mortality, although we identiﬁed a more
direct, positive association of SBP and PP with stroke. The
absence of an association between BP and nonfatal myocar-
dial infarction do not support a major pathophysiological role
of worsened myocardial ischemia at low BP.
Our data suggest an optimal predialysis BP target of 157/
90 mm Hg, a value substantially higher than that proposed
by current recommendations for hemodialysis patients.
However, the U-shaped association between BP and mor-
tality in dialysis patients remains a reason for uncertainty
and for the recommendation to perform a large randomized
clinical trial aimed at determining the ideal BP target for
antihypertensive therapy in dialysis patients. Until such a
trial becomes available, relatively low BP values should be
regarded as potentially deleterious in this particular patient
population. However, whether a target as low as 135/70
mm Hg should be used as the lower threshold warrants
additional studies.
METHODS
Participants
The French Observatory is a prospective, multicenter, epidemiologic
observational study with 169 participating dialysis facilities in
France. Details on enrollment and follow-up are described
elsewhere.30
In brief, all adult patients (18 years of age and older) receiving
maintenance hemodialysis therapy for at least 1 month were
eligible for inclusion. Enrollments began in June 2007 and ended
in June 2009, with the ﬁnal data collection in December 2009.
Data were collected using an electronic case-report system at
study entry and thereafter at 6x-month intervals up to 30 months
after entry (i.e., between 2 and 6 data collections per patient in
total).
Clinical events, serum biochemistry data, and information on
patient treatment were collected. At the baseline visit, demographic
characteristics, dialysis vintage, and history of cardiovascular disease
were recorded. The following data were also recorded at each
6-month collection point: SBP, DBP, serum levels of C-reactive
protein, phosphate, calcium, intact PTH and albumin, normalized
protein catabolic rate, history of parathyroidectomy, current med-
ications to control serum phosphate or blood hemoglobin con-
centrations, dialysis modality, antihypertensive drug treatment,
clinical endpoints (endpoints are deﬁned in the following para-
graph), and patient status (on dialysis, deceased, lost to follow-up,
kidney transplantation). All laboratory measurements were per-
formed locally. All data were anonymized, and electronic case
report forms were transmitted by each center to regional co-
ordinators who in turn forwarded them to a national coordinator
for ﬁnal data processing. All patients gave informed consent to
participate in the study, which was approved by the National Ethics
Committee.
Endpoints
The primary endpoint was all-cause mortality. Secondary endpoints
were cardiovascular mortality deﬁned as death directly related to
cardiovascular events (myocardial infarction, stroke) or sudden
death or death occurring without evident cause (such as cancer,
infection, traumatism). Other secondary endpoints were myocardial
infarction (deﬁned as nonfatal infarction documented by an682electrocardiogram, elevated serum troponin, or coronary angiog-
raphy evidence), stroke (deﬁned as nonfatal stroke with typical rapid
onset of symptoms or permanent neurologic deﬁcit), and amputa-
tion (deﬁned as nontraumatic amputation over the midfoot resulting
from obliterative arteriopathy).
BP parameters
SBP and DBP were the average BP of 3 weekly sessions, measured with
semiautomatic devices with the participants in the supine position and
resting for at least 5 minutes immediately before each dialysis session.
The PP was calculated as (SBP  DBP) and expressed in mm Hg.
Data presented here are compliant with the STROBE (Strength-
ening the Reporting of Observational Studies in Epidemiology)
reporting of observational studies.31
Statistics
In describing demographic, biochemical, and clinical data, mean 
SD or median (25th:75th) values were used for quantitative data
and frequency and proportion for qualitative data. Cox propor-
tional hazards models were used to calculate HRs for mortality at
the end of the study (December 2009). Potential covariates included
serum corrected albumin (according to the assay method used32),
serum C-reactive protein, serum phosphate, uncorrected serum
total calcium, plasma-corrected intact PTH (according to the assay
kit used33), hemoglobin dialysate calcium concentration (all as
continuous variables), use of an erythropoiesis-stimulating agent
therapy, presence of diabetes mellitus, history of cardiovascular
disease, use of antihypertensive therapy (all as yes/no variables),
and smoking history (no/past smoker/active smoker). We ran the
combined “mfp” and “stcrreg” Stata commands (StataCorp, College
Station, TX) (using backward elimination with a threshold of 0.20)
to test their effect in a proportional hazards Cox model, with
“transplantation” status as a competing risk34 (“stcrreg” command
that implements competing-risks regression based on Fine and
Gray’s proportional subhazards model) and circulating serum
phosphate, uncorrected total calcium, and corrected intact PTH
concentrations as fractional polynomials (“mfp” command).35 This
led to the exclusion of erythropoiesis-stimulating agent therapy and
dialysate calcium, whereas sex, age, and dialysis vintage were forced
in the ﬁnal base model, and new variables containing the fractional
polynomial powers for phosphate, total calcium, and corrected
intact PTH were generated. Hazard proportionality of covariates
was veriﬁed graphically using Schoenfeld residuals.
Components of BP (SBP, DBP, and PP) throughout the follow-up
period were tested against outcomes with an adjusted TVC linear
Cox model and an adjusted TVC fractional polynomial Cox model,
using “transplantation” as a competing risk for all-cause mortality,
and “transplantation” and “noncardiovascular death” as competing
risks for cardiovascular mortality. Due to the U-shaped HRs, frac-
tional polynomial Cox models were signiﬁcantly superior to linear
Cox models for the prediction of all-cause and cardiovascular
mortality and were therefore retained for result analyses. Interactions
between the components of BP and age, serum albumin concen-
tration, diabetes, history of cardiovascular disease and smoking, and
use of antihypertensive therapy were researched using the “mfpigen”
Stata command for interactions and fractional polynomials.
Also, the predictive ability of SBP, DBP, and PP with regard to
mortality throughout the follow-up was analyzed with a joint model
including both longitudinal measures of each BP component and its
rate of change (slope) over time,36 as joint models are reportedly less
sensitive to longitudinal missing values and measurement errors.37,38Kidney International (2016) 90, 674–684
T Hannedouche et al.: Blood pressure and survival in hemodialysis c l i n i ca l i nves t iga t ionOur joint model combined 2 submodels, the ﬁrst one being a longi-
tudinal mixed model with its own set of covariates (those signiﬁcant
when this longitudinal mixed submodel is tested alone with a ﬁxed
slope), predicting the value of the BP component measured every 6
months, whereas the second was a ﬂexible parametric survival sub-
model with 1 degree of freedom (0 interior knot and 2 boundary
knots), also with its own set of covariates (those of the preceding
deﬁnedmultivariate Cox base model) (Table 2), receiving the result of
the longitudinal submodel as a TVC combined with its slope (Stata
command “stjm”).39 This joint model, therefore, analyzed the asso-
ciation between outcomes and both exposure to components of BP
and the trends of variation over the follow-up period.
Statistical analyses were performed using Stata version 13 (Stata
Corp, College Station, TX). A P value <0.05 was considered to be
statistically signiﬁcant.DISCLOSURE
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Figure S1. Flow chart of the patients included for analysis.
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(B) and pulse pressure (C). Values were calculated in time-varying
covariate Cox models using fractional polynomials for the blood
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Table S4. Systolic BP trends: All-cause and cardiovascular mortality
according to SBP trends in hemodialysis patients using adjusted Cox
analysis.
Table S5. Diastolic BP trends: All-cause and cardiovascular mortality
according to DBP trends in hemodialysis patients using adjusted Cox
analysis.
Table S6. Pulse pressure trends: All-cause and cardiovascular mor-
tality according to pulse pressure trends in hemodialysis patients
using adjusted Cox analysis.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
REFERENCES
1. Lewington S, Clarke R, Qizilbash N, et al.; Prospective Studies
Collaboration. Age-speciﬁc relevance of usual blood pressure to vascular
mortality: a meta-analysis of individual data for one million adults in 61
prospective studies. Lancet. 2002;360:1903–1913.
2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the
prevention of cardiovascular disease: meta-analysis of 147 randomised
trials in the context of expectations from prospective epidemiological
studies. BMJ. 2009;338:b1665.Kidney International (2016) 90, 674–6843. Boutitie F, Gueyfﬁer F, Pocock S, et al.; INDANA Project Steering
Committee. INdividual Data ANalysis of Antihypertensive intervention.
J-shaped relationship between blood pressure and mortality in
hypertensive patients: new insights from a meta-analysis of individual-
patient data. Ann Intern Med. 2002;136:438–448.
4. Dorresteijn JA, van der Graaf Y, Spiering W, et al.; Secondary
Manifestations of Arterial Disease Study Group. Relation between blood
pressure and vascular events and mortality in patients with manifest
vascular disease: J-curve revisited. Hypertension. 2012;59:14–21.
5. Li Z, Lacson E Jr, Lowrie EG, et al. The epidemiology of systolic blood
pressure and death risk in hemodialysis patients. Am J Kidney Dis. 2006;
48:606–615.
6. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Reverse
epidemiology of hypertension and cardiovascular death in the
hemodialysis population: the 58th annual fall conference and scientiﬁc
sessions. Hypertension. 2005;45:811–817.
7. Stidley CA, Hunt WC, Tentori F, et al.; Medical Directors of Dialysis
Clinic Inc. Changing relationship of blood pressure with mortality
over time among hemodialysis patients. J Am Soc Nephrol. 2006;17:
513–520.
8. Chang TI, Friedman GD, Cheung AK, et al. Systolic blood pressure and
mortality in prevalent haemodialysis patients in the HEMO study. J Hum
Hypertens. 2011;25:98–105.
9. Robinson BM, Tong L, Zhang J, et al. Blood pressure levels and mortality
risk among hemodialysis patients in the Dialysis Outcomes and Practice
Patterns Study. Kidney Int. 2012;82:570–580.
10. Molnar MZ, Lukowsky LR, Streja E, et al. Blood pressure and survival in
long-term hemodialysis patients with and without polycystic kidney
disease. J Hypertens. 2010;28:2475–2484.
11. Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and
control of hypertension in chronic hemodialysis patients in the United
States. Am J Med. 2003;115:291–297.
12. Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse
pressure and mortality in patients undergoing maintenance
hemodialysis. JAMA. 2002;287:1548–1555.
13. REIN Registry. 2010 Annual report. Agence de Biomedecine. Available at:
http://www.agence-biomedecine.fr/IMG/pdf/2012_rapport_annuel_rein.
pdf. Accessed September 9, 2014.
14. Agarwal R. Exploring the paradoxical relationship of hypertension with
mortality in chronic hemodialysis. Hemodial Int. 2004;8:207–213.
15. Bansal N, McCulloch CE, Rahman M, et al.; CRIC Study Investigators.
Blood pressure and risk of all-cause mortality in advanced chronic kidney
disease and hemodialysis: the Chronic Renal Insufﬁciency Cohort study.
Hypertension. 2015;65:93–100.
16. Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets
during dialysis improves control but increases intradialytic hypotension.
Kidney Int. 2008;73:759–764.
17. McIntyre CW. Effects of hemodialysis on cardiac function. Kidney Int.
2009;76:371–375.
18. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the
heart of uremic patients. J Am Soc Nephrol. 1998;9:1018–1022.
19. Park J, Rhee CM, Sim JJ, et al. A comparative effectiveness research study
of the change in blood pressure during hemodialysis treatment and
survival. Kidney Int. 2013;84:795–802.
20. Lertdumrongluk P, Streja E, Rhee CM, et al. Changes in pulse pressure
during hemodialysis treatment and survival in maintenance dialysis
patients. Clin J Am Soc Nephrol. 2015;10:1179–1191.
21. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular
disease in dialysis patients. Am J Kidney Dis. 2005;45(suppl 3):S1–S153.
22. Treatment of Adults and Children with Renal Failure Standards and Audit
Measures. 3rd ed. London: Renal Association Standards, Royal College of
Physicians London; 2002.
23. Agarwal R, Peixoto AJ, Santos SF, Zoccali C. Pre- and postdialysis blood
pressures are imprecise estimates of interdialytic ambulatory blood
pressure. Clin J Am Soc Nephrol. 2006;1:389–398.
24. Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood pressure and mortality in
U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med.
2013;159:233–242.
25. Kooman JP, Gladziwa U, Böcker G, et al. Blood pressure during the
interdialytic period in haemodialysis patients: estimation of representative
blood pressure values. Nephrol Dial Transplant. 1992;7:917–923.
26. Yang CY, Yang WC, Lin YP. Postdialysis blood pressure rise predicts long-
term outcomes in chronic hemodialysis patients: a four-year prospective
observational cohort study. BMC Nephrol. 2012;13:12–22.683
c l i n i ca l i nves t iga t i on T Hannedouche et al.: Blood pressure and survival in hemodialysis27. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive
drugs in dialysis patients: systematic review and meta-analysis.
Hypertension. 2009;53:860–866.
28. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood
pressure on cardiovascular events and mortality in patients on dialysis: a
systematic review and meta-analysis of randomised controlled trials.
Lancet. 2009;373:1009–1015.
29. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year
survivalin dialysis patients with dilated cardiomyopathy: a
prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:
1438–1444.
30. Fouque D, Roth H, Pelletier S, et al. Control of mineral metabolism and
bone disease in haemodialysis patients: which optimal targets? Nephrol
Dial Transplant. 2013;28:360–367.
31. von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. The
Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) statement: guidelines for reporting observational studies.
Ann Intern Med. 2007;147:573–577.
32. Carfray A, Patel K, Whitaker P, et al. Albumin as an outcome measure in
haemodialysis in patients: the effect of variation in assay method.
Nephrol Dial Transplant. 2000;15:1819–1822.
33. Souberbielle JC, Roth R, Fouque D. Parathyroid hormone measurement
in CKD. Kidney Int. 2010;77:93–100.
34. Noordzij M, Leffondré K, van Stralen KJ, et al. When do we need
competing risks methods for survival analysis in nephrology? Nephrol
Dial Transplant. 2013;28:2670–2677.
35. Royston P, Sauerbrei W. Building multivariable regression models with
continuous covariates in clinical epidemiology–with an emphasis on
fractional polynomials. Methods Inf Med. 2005;44:561–571.
36. Li L, Hu B, Greene T. A semiparametric joint model for longitudinal and
survival data with application to hemodialysis study. Biometrics. 2009;65:
737–745.
37. Wu L, Liu W, Yi GY, Huang Y. Analysis of longitudinal and survival data:
joint modeling, inference methods, and issues. J Probabil Stat. 2012;2012.
article ID 64053.
38. Crowther MJ, Lambert PC, Abrams KR. Adjusting for measurement error
in baseline prognostic biomarkers included in a time-to-event analysis: a
joint modelling approach. BMC Med Res Methodol. 2013;13:146.
39. Crowther MJ, Abrams KR, Lambert PC. Joint modeling of longitudinal
and survival data. Stata J. 2013;13:165–184.APPENDIX
Regional Study Coordinators
Lahcene Attroun, Raymond Azar, Pierre Bories, Agnès Caillette-
Beaudouin, Bernard Canaud, Gabriel Choukroun, Vincent Esnault,
Mohamed Hammadi, Thierry Hannedouche, Patrick Henri, Philippe
Honoré, Belkacem Issad, Dominique Joly, Eric Laruelle, Gildas Le Mao,
Sylvain Marchais, Benoît Vendrely, and Philippe Zaoui.
Study Investigators
Larbi Aazib, Abdelhamid Abbassi, Elias Abdullah, Habib Abou-Bekr,
Carine Achard-Hottelart, Geneviève Achin, Salima Ahriz-Saksi, Mahen
Albadawy, Catherine Albert, Samir Albitar, Farideh Alenabi, Mahmoud
Allouache, Amar Amaouche, Brahim Amara, Mounia Ammor, Kim
Seng Ang, Ubald Assogba, Lynda Azzouz, Chérif Badid, Juliette
Baleynaud, Evelyne Bargas, Emmanuel Baron, François Basse,
Jean-Marie Batho, Marc Bauwens, Dorothée Bazin, Abdelmajid Ben
Aicha, Seddik Benarbia, Larbi Bencheikh, Jean-Christophe Bendini,
Djeleddine Benyakoub, Dominique Bergua, Catherine Bessin, Luc
Billaux, Stéphane Billion, Haïat Bittar, Jean-Paul Bocquet, Hervé
Bonarek, Claude Bonniol, Jean-Sébastien Borde, Samir Boubenider,
Rémi Boudet, Waël Boudi, Loreley Boudier, Djema Bouguern,684M Boukelmoune, Fatha Zohra Boukhalfa, Henri Boulanger, Philippe
Bouvier, Mouloud Bouzernidj, Mohamed Brahim Bounab, José
Brasseur, Laura Braun, Marie Briet, Doan Bui-Quang, Sebastien Canet,
Eric Canivet, Jorge Cardozo, Carlos Cardozo, Baher Chaghouri,
Mokhtar Chawki, Charles Chazot, Philippe Choulet, Pierre Clavel,
Jean-Philippe Coindre, Olivier Coldefy, M.A. Colomina, François
Combarnous, Christian Dabot, Djamal Dahmane, Ahmed Dahmani,
Daniel Daubresse, Jean-François De Fremont, Valérie De Precigout,
Françoise Dehais, M. Dehina, Caroline Delclaux, Yashou Delmas,
Coralia Denicola, Jean-Philippe Devaux, Raji Diab, Zineddine
Diddaoui, Professor Didelot, Yves Dimitrov, Assia Djema, Patrick
Donnadieu, Valérie Drouillat, Olivier Drouineau, Geneviève Dumont,
Philippe Dupuy, Pierre-Yves Durand, Stéphane Edet, Hamid El Ali,
Khuzama El Nasser, Christian Emond, Baya Fadel, Mohamed Fakir,
Jean-Paul Faucon, André Faure, Assia Ferhat-Carre, Hafedh Fessi,
Rocsana Fickl, Mahammed Fodil-Cherif, Jacques Fourcade, Philippe
Fournier, Rabah Fraoui, Olivier Fritz, Elke Gaboriau, Alexandre Ganea,
Roula Galland, Jacqes Gaultier, Eric Gauthier, Sylvie Geffroy
Guiberteau, Sandrine Genestier, Patrick Giraud, Françoise Glowacki,
Christophe Goupy, Pierre Grimal, Mounir Guergour, Jean Gugliotta,
Marie-Paule Guillodo, Marie-Claude Guimont, Touﬁc Hachache, Sabria
Hacini, Imad Haddad, Mohamed Hadj-Abdelkader, Pascale Halin,
Patrick Hallonet, Nasser Hamdini, Didier Hamel, Françoise Heibel,
Alain Hermelin, Alim Heyani, Philippe Hiernaux, Maxime Hoffmann,
Valérie Hugot, Richard Ibos, Dominque Jacq, Jean-Paul Jaulin,
Guillaume Jean, Philippe Jousset, Benoît Jonon, Véronique Joyeux,
Laurent Juillard, Amer Kamal, Mimi Kareche Chibout, Rateb Khayat,
Franklin Khazine, Karim Khellaf, Arnaud Klisnick, Yannick Knefati,
A. Kolko-Labadens, Amir Kolta, Niloufar Kossari, Olivier Kourilsky,
Nicolas Krayem, Marc Kribs, Thierry Krummel, François Kuentz, Kristian
Kunz, Christian Lamotte, Jean-Marc Lanau, Isabelle Landru, Achour
Laradi, Nicole Larroumet, Olivier Lavelle, Frank Le Roy, Alejandra Lenz,
Denis Lerda, Fanny Leroy, Marc Leteif, Martial Levannier, Thierry
Lobbedez, Hassan Lockmane, Nathalie Longlune, Christie Lorriaux
Mortuaire, Alain Lyon, Ghassan Maakaroun, Mehadji Maaz, Eric
Magnant, Ghandour Majdalani, Jean-Luc Mahe, Edward Maksour,
Stéphane Martin, Catherine Martinat-Calvo, Valérie Masson, Delia
May, Claire Maynard, Brice Mayor, Omar Mazouz, Hocine Mehama,
Dominique Mercier, Gilles Messier, Robert Milongo, Nicole Monnier,
Karine Moreau, Xavier Moreau-Gaudry, Bertrand Morel, Luc
Moulonguet Doleris, Alexandre Mouneimne, Catherine Mourey-Epron,
Françoise Moussion, Blanca Muniz, J. Mustel, Rachida Nebbad, Fazia
Nemmar, Sylvie Neuville, Tien Nguyen-Quang, Patrice Nolen, Michel
Normand, Emerson N’Sembani, Jacques Ollier, Jean-Paul Ortiz,
Messaoud Ouziala, Bernard Painchart, Pedro Palacin, Josette
Pengloan, Franck Perrin, Bruno Perrone, Philippe Petitjean,
Dominique Petregne, Jean-Baptiste Philit, Vincent Planquois, Marc
Pocheville, Jacky Potier, Jean-Michel Poux, Olivier Puyoo, Catherine
Quere-Maurouard, Ahmed Rachi, Anderson Ratsimbazafy, Matthieu
Reberolle, Henri Renaud, Bernard Richalet, Sarah Richter, Philippe
Rieu, Michel Rince, Odile Rivault, Alain Robert, Jacques Rottembourg,
Philippe Rousseau, Sophie Rubens Duval, Christa Roubicek, Piotr
Seniuta, Pascal Seris, Irina Shahapuni, Reda Sharobeem, Milad
Shenouda, Hélène Sichez Com, Danlèle Simonin, Nadia Soltani, Marc
Souid, Hadia Sow, Jean-Christophe Szelag, Catherine Taddei, Zafer
Takla, Dominque Teboulle, Jean-Claude Terrat, Patrick Thomas, Adam
Tifoura, Jacques Toulon, Dominique Touzard, Pablo Urena Torres, Hans
Van der Pijl, Thierry Vanel, Carlos Vela, Isabelle Vernier, Cathy Verove,
François Pascal Wambergue, BassemWehbe, Maeva Wong-Fat, Fatima
Yazbeck, Djamal Yousﬁ, Maan Youssef, and Abdelaziz Ziane.Kidney International (2016) 90, 674–684
